Publication | Closed Access

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

First-line PembrolizumabUrologyMetastatic Urothelial CancerGenitourinary CancerMedicineImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyCisplatin-ineligible Patients